Trial
NCT03168438
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
Merck Sharp & Dohme LLC
Condition
Neoplasms
Intervention
Letetresgene autoleucel
Why stopped
The study was terminated following an internal review of the company's research and development portfolio
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-11